News
Generally, fighting cancer is about delivering a relentless attack on the spreading disease, but a new approach explores the possible benefits of toggling therapy off and on like a light switch, ...
2d
The Times of Israel on MSNZelig Eshhar, leading cancer researcher and immunologist, dies at 84Research by Weizmann Institute scientist and Israel Prize winner saved 'countless lives,' was basis for technology sold for ...
A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of ...
From FDA approvals streamlining access to critical therapies to new breakthroughs in challenging malignancies, the field of cancer care continues to demonstrate remarkable progress.
While data is promising, many questions remain about topics such as timing and doses in the treatment of hematologic malignancies.
A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...
4d
News-Medical.Net on MSNLeukemia-on-a-chip offers breakthrough in personalized cancer treatmentA team of researchers led by NYU Tandon School of Engineering's Weiqiang Chen has developed a miniature device that could ...
During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy referrals, timing, and challenges in relapsed ...
4d
Interesting Engineering on MSNCredit-card-sized chip reveals how immune cells hunt and kill cancer in real timeEngineered chip mimics bone marrow and immune system, offering a faster, tailored path for cancer immunotherapy.
Previously, due to the risk of cytokine release syndrome and neurological toxicities, many CAR T-cell therapies included a REMS requirement.
Thermo Fisher Scientific Inc. (NYSE:TMO) ranks among the best CRISPR stocks to buy. On June 24, Thermo Fisher Scientific Inc.
The long-term benefits of CAR T-cell therapy, the use of residual disease activity to direct treatment, and a novel drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results